STEPHANE Roze, France
HEVA HEOR HEALTH ECONOMICSPresenter of 1 Presentation
COST EFFECTIVENESS ANALYSIS OF MINIMEDTM 670G SYSTEM VERSUS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION, IN INDIVIDUALS WITH TYPE1 DIABETES IN THE UNITED KINGDOM
Abstract
Background and Aims
This study assesses the long-term cost-effectiveness of the MiniMedTM 670G hybrid closed loop system versus Continuous Subcutaneous Insulin Infusion (CSII) alone in people with type 1 diabetes (T1D) in UK.
Methods
The IQVIA-CORE-Diabetes-Model was used to perform cost-effectiveness analysis over patient lifetime. Clinical data were sourced from pivotal clinical study comparing MiniMedTM 670G system with CSII in people with T1D; in which the use of MiniMedTM 670G system was associated with a reduction in HbA1c of 0.5% (5.5 mmol/mol), from 7.4% (57 mmol/mol) at baseline to 6.9% (52 mmol/mol) at the end of the study. Cost data, expressed in 2018 British pounds (GBP), were obtained from UK reference-prices and the published literature.
Results
The MiniMedTM 670G system was associated with a quality-adjusted life-year (QALY) gain of 1.74 but higher overall costs versus CSII, leading to an incremental cost-effectiveness ratio (ICER) of GBP 20,421 per QALY gained. Use of MiniMedTM 670G system resulted in a lower cumulative incidence of diabetes-related complications. Higher MiniMedTM 670G system acquisition costs were partially offset by reduced complication costs. In patients with HbA1c≥7.5% at baseline, MiniMedTM 670G system was associated with 2.02 incremental QALYs versus CSII, yielding an ICER of GBP12,892 per QALY gained. Extensive sensitivity analysis on key drivers confirmed the robustness of results.
Conclusions
The MiniMedTM 670G system was associated with clinical benefits and quality of life improvements in people with T1D relative to CSII. At a willingness-to-pay threshold of GBP20,000 per QALY-gained, MiniMedTM 670G System likely represents a cost-effective treatment option for people with T1D in UK.